AtriCure, Inc. 10-Q Summary: Quarter Ended September 30, 2008
Business Context and Reporting Period
AtriCure, Inc. is a medical device company focused on the surgical treatment of atrial fibrillation (AF). The company develops, manufactures, and sells cardiac ablation products, primarily the Isolator bipolar ablation system. This report covers the quarterly period ended September 30, 2008. The company operates as a single segment with sales in the United States and internationally (primarily Europe, Asia, South America, and Canada).
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 |
|---|---|---|
| Revenues | $14.80 million | $43.19 million |
| Gross Profit | $11.41 million (77.1% margin) | $33.07 million (76.6% margin) |
| Net Loss | $(1.77) million | $(6.97) million |
| Loss Per Share (Basic/Diluted) | $(0.12) | $(0.49) |
| Cash and Cash Equivalents | $12.28 million | $12.28 million (Ending Balance) |
| Restricted Cash | $6.00 million | $6.00 million |
| Total Debt (Current + Long-term) | $6.08 million | $6.08 million |
| Working Capital | $19.47 million | $19.47 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 22.8% year-over-year for the quarter and 22.9% for the nine-month period, driven by increased unit sales of existing products and the introduction of new products (ORlab mapping system and Coolrail linear ablation device).
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased $0.4 million for the quarter and $2.4 million for the nine months, primarily due to higher sales compensation. However, SG&A as a percentage of revenue decreased significantly (from 81.3% to 69.0% for the quarter) due to revenue growth outpacing expense growth.
- Debt Structure: On July 1, 2008, the company entered a new $10 million revolving credit facility with National City Bank, replacing a previous facility with Lighthouse Capital Partners. As of September 30, 2008, $6 million was drawn on the new facility, and $6 million was placed in a restricted cash account to secure the line.
- Net Loss Improvement: The net loss narrowed to $1.77 million for the quarter compared to $2.60 million in the prior year quarter, and $6.97 million for the nine months compared to $9.69 million in the prior year.
Guidance, Outlook, Risks, and Contingencies
- Regulatory and Clinical Trials: The company is conducting the ABLATE clinical trial to evaluate the Isolator system for permanent and persistent AF. FDA approval for open procedures to treat permanent AF is targeted for as early as 2010. A trial for a left atrial appendage exclusion system began enrollment in October 2008.
- Legal Proceedings:
- Class Action Lawsuit: A securities class action lawsuit (Levine v. AtriCure) regarding the 2005 IPO remains pending; a motion to dismiss was denied, and a motion for reconsideration is pending.
- DOJ Investigation: The U.S. Department of Justice is investigating potential False Claims Act violations regarding marketing practices for off-label use (treating AF) and potential incorrect Medicare billing codes. The company is cooperating with document requests.
- Liquidity: Management believes current cash, cash equivalents, and credit facility availability are sufficient to meet needs for at least the next 12 months. However, the company notes that if additional financing is required, it may need to reduce R&D or marketing efforts.
- Market Risks: The company faces risks related to global economic volatility affecting elective procedure volumes, foreign currency exchange fluctuations (Euro vs. USD), and interest rate changes on variable-rate debt.
Key Facts for Investor Verification
- DOJ Investigation Status: Verify the scope and potential financial impact of the Department of Justice investigation into off-label marketing and Medicare billing practices.
- Credit Facility Covenants: Confirm compliance with the new National City Bank credit facility covenants, specifically the requirement to maintain a loss before interest, taxes, depreciation, and amortization (EBITDA) of no more than $15 million per annum.
- Clinical Trial Progress: Monitor enrollment and results of the ABLATE trial and the left atrial appendage exclusion system trial, as FDA approval for AF treatment is critical for future growth.
- Restricted Cash: Note that $6 million of the company's cash is restricted and tied to the credit facility, limiting immediate liquidity for other uses.
- Class Action Litigation: Track the status of the pending motion for reconsideration regarding the securities class action lawsuit.